tazobactam has been researched along with beta-lactams in 49 studies
Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (beta-lactams) | Trials (beta-lactams) | Recent Studies (post-2010) (beta-lactams) |
---|---|---|---|---|---|
1,327 | 153 | 694 | 7,579 | 179 | 3,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (12.24) | 18.2507 |
2000's | 17 (34.69) | 29.6817 |
2010's | 19 (38.78) | 24.3611 |
2020's | 7 (14.29) | 2.80 |
Authors | Studies |
---|---|
Livermore, DM; Seetulsingh, P | 1 |
Inoue, E; Mitsuhashi, S; Muratani, T; Nakane, T; Yokota, E | 1 |
Jin, YF; Piddock, LJ; Turner, HL | 1 |
Czajkowski, DP; Hanehara-Kunugita, C; Hyodo, A; Maiti, SN; Micetich, RG; Phillips, OA; Singh, MP; Spevak, P | 1 |
Giakkoupi, P; Legakis, NJ; Tzelepi, E; Tzouvelekis, LS | 1 |
Degnan, BA; Farmer, TH; Payne, DJ | 1 |
Ceesay, TP; Gesser, R; Graham, DR; Holtom, P; Lucasti, C; Malafaia, O; McAdams, A; Nichols, RL; Perez, NQ; Woods, GL | 1 |
Citron, DM; Gesser, RM; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, Y | 1 |
Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
Zaĭtsev, AA | 1 |
Adeyi, B; Angel-Muller, E; Hague, C; Higareda, I; Ismail, M; Roy, S; Teppler, H; Woods, GL | 1 |
Anderson, VE; Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM; Hujer, KM | 1 |
Fosse, T; Giraud-Morin, C; Madinier, I | 1 |
Gesser, RM; McCarroll, KA; Woods, GL | 1 |
Higgins, PG; Seifert, H; Stefanik, D; Wisplinghoff, H | 1 |
Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM | 1 |
Burgess, DS; Hall, RG | 1 |
Cross, SE; Dalley, AJ; Lipman, J; Roberts, MS; Rudd, M; Venkatesh, B | 1 |
Bonomo, RA; Buynak, JD; Carey, PR; Helfand, MS; Taracila, MA; Totir, MA; van den Akker, F | 1 |
Anuradha, K; Lakshmi, V; Sailaja, VV; Satheesh, T; Umabala, P | 1 |
Lipman, J; Paratz, JD; Roberts, JA | 1 |
Kuo, HY; Lin, ML; Liu, CY; Wang, FD; Yen, YF | 1 |
An, MM; Chen, ML; Jiang, YY; Liu, P; Shen, H; Wang, R; Zhang, JD; Zou, Z | 1 |
Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M | 1 |
De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
Amancio Martins, W; Bahia, JL; Cara, DC; Coutinho, SC; DE Macedo Farias, L; Galuppo Diniz, C; Lopes DE Andrade, JP; Morais Apolonio, AC; Nicoli, JR; Roque DE Carvalho, MA; Valéria Dos Santos, K | 1 |
Buyle, F; Claus, B; Robays, H; Vogelaers, D | 1 |
Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
Arakawa, Y; Fujita, A; Jin, W; Kimura, K; Mikamo, H; Suematsu, H; Wachino, J; Yamada, K; Yamagishi, Y; Yokoyama, S | 1 |
Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
Borgia, G; Gentile, I; Maraolo, AE | 1 |
Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F | 1 |
Dizbay, M; Karaşahin, EF; Karaşahin, Ö; Özger, HS | 1 |
Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
Aubron, C; Corallo, C | 1 |
Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
An, G; Bach, T; D'Cunha, R; Li, P; Nalbant, D; Winokur, P; Young, BA; Zhang, J | 1 |
Floch, P; Gaudru, C; Guet-Revillet, H; Massip, C; Mathieu, C; Miaut, V; Oswald, E; Segonds, C | 1 |
Barnes, SW; Dean, CR; Iartchouk, O; Jones, AK; Lee, PS; Mostafavi, M; Ranjitkar, S; Walker, JR; Willis, TW; Zwirko, Z | 1 |
Baldassarre, M; Barsic, B; Bartoletti, M; Bernardi, M; Bruns, T; Burra, P; Calbo, E; Caraceni, P; Cobos-Trigueros, N; D'Offizi, G; Domenicali, M; Galan-Ladero, MA; Giannella, M; Lewis, RE; Maraolo, AE; Merli, M; Muñoz, P; Paul, M; Petrosillo, N; Retamar, P; Rodriguez-Baño, J; Schramm, C; Seminari, E; Tedeschi, S; Torrani Cerenzia, M; Tumbarello, M; Verucchi, G; Viale, P; Zak-Doron, Y | 1 |
Albanèse, J; Bornet, C; Curti, C; Fersing, C; Guinard, B; Lamy, E; Mathias, F; Primas, N; Souab, HK; Vanelle, P | 1 |
Cardoso, MH; Costa, BO; Franco, OL | 1 |
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
Bassetti, M; Giacobbe, DR; Pelosi, P; Robba, C; Vena, A | 1 |
Burgess, DS; Clark, JA; Landmesser, KB | 1 |
Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
Alosaimy, S; Amaya, L; Biagi, M; Chandler, E; Cubillos, A; Davis, SL; Finch, N; Hobbs, ALV; Holger, D; Jorgensen, SCJ; Kufel, WD; Kunz Coyne, AJ; Lagnf, AM; Li, D; Molina, KC; Moore, WJ; Morrisette, T; Mubarez, M; Patch, M; Polisetty, RS; Rebold, N; Rico, M; Rybak, MJ; Sakoulas, G; Simon, SP; Smith, IMK; Tran, NN; Truong, J; Venugopalan, V; Veve, MP; Witucki, P; Wrin, J; Yost, C | 1 |
Gehlot, P; P, H | 1 |
4 review(s) available for tazobactam and beta-lactams
Article | Year |
---|---|
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2009 |
Development of Peptides that Inhibit Aminoglycoside-Modifying Enzymes and β-Lactamases for Control of Resistant Bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacterial Infections; beta-Lactamases; beta-Lactams; Clavulanic Acid; Drug Design; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Kanamycin Kinase; Nucleotidyltransferases; Sulbactam; Tazobactam | 2020 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Cyclooctanes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Public Health; Sepsis; Tazobactam | 2020 |
7 trial(s) available for tazobactam and beta-lactams
Article | Year |
---|---|
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Skin Diseases; Staphylococcus aureus; Tazobactam; Treatment Outcome | 2002 |
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Double-Blind Method; Enzyme Inhibitors; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Bacterial; Tazobactam | 2002 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
[Carbapenem antibiotic ertapenem in the treatment of extrahospital intraabdominal infections].
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2003 |
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lactams; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Tazobactam; Treatment Outcome | 2003 |
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Infusions, Intravenous; Lactams; Logistic Models; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Skin Diseases; Statistics, Nonparametric; Tazobactam; Treatment Outcome | 2004 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
38 other study(ies) available for tazobactam and beta-lactams
Article | Year |
---|---|
Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Clavulanic Acids; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Escherichia coli; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1993 |
Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Lactams; Penicillanic Acid; Sulbactam; Tazobactam | 1993 |
SYN-1012: a new beta-lactamase inhibitor of penem skeleton.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Drug Synergism; Enzyme Inhibitors; Humans; Lactams; Male; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Rabbits; Tazobactam | 1997 |
Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Asparagine; Aspartic Acid; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli; Inhibitory Concentration 50; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 1999 |
Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Cell Membrane Permeability; Clavulanic Acid; Enterobacter cloacae; Enzyme Inhibitors; Escherichia coli; Gram-Negative Bacteria; Klebsiella pneumoniae; Lactams; Penicillanic Acid; Periplasm; Sulbactam; Tazobactam | 1999 |
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
Topics: Ampicillin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Binding, Competitive; Clavulanic Acid; Drug Resistance, Microbial; Enzyme Inhibitors; Escherichia coli; Kinetics; Models, Chemical; Mutagenesis; Mutagenesis, Site-Directed; Penicillanic Acid; Plasmids; Serine; Tazobactam; Thermodynamics; Time Factors | 2003 |
[Phenotypes of beta-lactam resistance in the genus Aeromonas].
Topics: Aeromonas; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Enzyme Inhibitors; Isoelectric Focusing; Isoelectric Point; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Tazobactam | 2003 |
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Clavulanic Acid; DNA; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam | 2004 |
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Escherichia coli; Escherichia coli Infections; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2004 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; beta-Lactams; Burns; Cephalothin; Debridement; Drug Administration Schedule; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam | 2007 |
Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Crystallography, X-Ray; Enzyme Inhibitors; Glycine; Penicillanic Acid; Serine; Spectrum Analysis, Raman; Stereoisomerism; Tazobactam | 2007 |
Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
Topics: Acinetobacter; Amoxicillin; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactams; Clavulanic Acid; Enterobacteriaceae; Enzyme Inhibitors; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas; Stenotrophomonas; Tazobactam; Ticarcillin | 2007 |
Continuous infusion of beta-lactams in the intensive care unit--best way to hit the target?
Topics: Anti-Bacterial Agents; beta-Lactams; Body Fluids; Epithelium; Humans; Infusions, Intravenous; Intensive Care Units; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Tazobactam | 2008 |
In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Cefoperazone; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sulbactam; Tazobactam | 2009 |
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam | 2010 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; beta-Lactam Resistance; beta-Lactams; Ertapenem; Germ-Free Life; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Tazobactam; Virulence | 2010 |
Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Administration Routes; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2010 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Japan; Klebsiella Infections; Klebsiella oxytoca; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Tazobactam | 2015 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Superinfection; Tazobactam; Treatment Outcome | 2016 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
β-Lactams Dosing in Overweight Critically Ill Patients: Are We Driving in the Dark?
Topics: beta-Lactams; Critical Illness; Humans; Obesity; Overweight; Tazobactam | 2017 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam | 2018 |
In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactams; Burkholderia cepacia complex; Burkholderia gladioli; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Tazobactam | 2019 |
Target (MexB)- and Efflux-Based Mechanisms Decreasing the Effectiveness of the Efflux Pump Inhibitor D13-9001 in
Topics: beta-Lactams; Imipenem; Microbial Sensitivity Tests; Monobactams; Piperidines; Pseudomonas aeruginosa; Quaternary Ammonium Compounds; Tazobactam; Thienamycins; Transcriptome | 2019 |
Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Female; Humans; Infusions, Intravenous; Liver Cirrhosis; Male; Middle Aged; Piperacillin; Prospective Studies; Retrospective Studies; Tazobactam; Treatment Outcome | 2019 |
Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; beta-Lactams; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam; Vancomycin | 2023 |
Computational and data mining studies to understand the distribution and dynamics of Temoneria (TEM) β-lactamase and their interaction with β-lactam and β-lactamase inhibitors.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Data Mining; Molecular Docking Simulation; Monobactams; Penicillins; Tazobactam | 2022 |